Literature DB >> 24673482

Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution.

Sherrill J Slichter1, Doug Bolgiano, Jill Corson, Mary Kay Jones, Todd Christoffel, S Lawrence Bailey, Esther Pellham.   

Abstract

BACKGROUND: Platelet (PLT) concentrates (PCs) prepared from whole blood in the United States are made using the PLT-rich plasma method. The PCs must be made within 8 hours of blood collection and stored for only 5 days. In Europe and Canada, PCs are made using the buffy coat (BC) method from whole blood held overnight at 22 °C and storage times may be up to 7 days. Our studies were designed to determine how long BC PLTs can be stored in plasma or Plasmalyte while meeting the FDA's poststorage viability criteria. STUDY DESIGN AND METHODS: Normal subjects donated whole blood that was stored at 22 °C for 22 ± 2 hours before preparation of BC PLTs. PLTs were stored for 5 to 8 days in either plasma or Plasmalyte concentrations of 65 or 80%. Radiolabeled autologous stored versus fresh PLT recoveries and survivals were assessed as well as poststorage in vitro assays.
RESULTS: BC PLTs stored in either plasma or 65% Plasmalyte met FDA poststorage PLT recovery criteria for 7 days but survivals for only 6 days, while storage in 80% Plasmalyte gave very poor results. Both stored PLT recoveries and survivals correlated with the same donor's fresh results, but the correlation was much stronger between recoveries than survivals. In vitro measures of extent of shape change, morphology score, and pH best predicted poststorage PLT recoveries, while annexin V binding best predicted PLT survivals.
CONCLUSION: BC PLTs stored in either plasma or 65% Plasmalyte meet FDA's poststorage viability criteria for 6 days.
© 2014 AABB.

Entities:  

Mesh:

Year:  2014        PMID: 24673482      PMCID: PMC4267475          DOI: 10.1111/trf.12634

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  19 in total

Review 1.  Additive solutions for the storage of platelets for transfusion.

Authors:  H Gulliksson
Journal:  Transfus Med       Date:  2000-12       Impact factor: 2.019

2.  Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or Plasmalyte.

Authors:  Sherrill J Slichter; Doug Bolgiano; Jill Corson; Mary Kay Jones; Todd Christoffel
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

3.  A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7-day-stored PLT-rich plasma and buffy coat PLTs from the same subjects.

Authors:  Larry J Dumont; Deborah F Dumont; Zoe M Unger; Alan Siegel; Zbigniew M Szczepiorkowski; Jill S Corson; Mary Kay Jones; Todd Christoffel; Esther Pellham; S Lawrence Bailey; Sherrill J Slichter
Journal:  Transfusion       Date:  2011-01-07       Impact factor: 3.157

Review 4.  Efficacy evaluation of current and future platelet transfusion products.

Authors:  Jaroslav G Vostal
Journal:  J Trauma       Date:  2006-06

5.  A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion.

Authors:  S Holme; G Moroff; S Murphy
Journal:  Transfusion       Date:  1998-01       Impact factor: 3.157

6.  The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability.

Authors:  S Holme; J D Sweeney; S Sawyer; M D Elfath
Journal:  Transfusion       Date:  1997-01       Impact factor: 3.157

7.  Preparation of leucocyte-poor platelet concentrates from buffy coats. IV. Clinical evaluation.

Authors:  R N Pietersz; H W Reesink; P C Huijgens; M H van Oers
Journal:  Vox Sang       Date:  1988       Impact factor: 2.144

8.  Paired comparison of platelet concentrates prepared from platelet-rich plasma and buffy coats using a new technique with 111In and 51Cr.

Authors:  T Keegan; A Heaton; S Holme; M Owens; E Nelson; R Carmen
Journal:  Transfusion       Date:  1992-02       Impact factor: 3.157

9.  A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipients.

Authors:  A Shanwell; S Larsson; J Aschan; O Ringdén
Journal:  Eur J Haematol       Date:  1992-08       Impact factor: 2.997

10.  Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium.

Authors:  F Bertolini; P Rebulla; D Riccardi; M Cortellaro; M L Ranzi; G Sirchia
Journal:  Transfusion       Date:  1989-09       Impact factor: 3.157

View more
  3 in total

1.  Assessment of Time-Dependent Platelet Activation Using Extracellular Vesicles, CD62P Exposure, and Soluble Glycoprotein V Content of Platelet Concentrates with Two Different Platelet Additive Solutions.

Authors:  Sami Valkonen; Birte Mallas; Ulla Impola; Anne Valkeajärvi; Juha Eronen; Kaija Javela; Pia R-M Siljander; Saara Laitinen
Journal:  Transfus Med Hemother       Date:  2019-05-07       Impact factor: 3.747

2.  Effects of the COVID-19 pandemic on supply and use of blood for transfusion.

Authors:  Simon J Stanworth; Helen V New; Torunn O Apelseth; Susan Brunskill; Rebecca Cardigan; Carolyn Doree; Marc Germain; Mindy Goldman; Edwin Massey; Daniele Prati; Nadine Shehata; Cynthia So-Osman; Jecko Thachil
Journal:  Lancet Haematol       Date:  2020-07-03       Impact factor: 18.959

3.  Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates.

Authors:  Irene Marini; Konstanze Aurich; Rabie Jouni; Stefanie Nowak-Harnau; Oliver Hartwich; Andreas Greinacher; Thomas Thiele; Tamam Bakchoul
Journal:  Haematologica       Date:  2018-08-16       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.